Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1,487 JPY | -1.75% | -2.65% | -11.80% |
Sales 2024 | 1,604B 10.3B | Sales 2025 * | 1,671B 10.73B | Capitalization | 2,666B 17.12B |
---|---|---|---|---|---|
Net income 2024 | 17.04B 109M | Net income 2025 * | 89.55B 575M | EV / Sales 2024 | 1.84 x |
Net Debt 2024 * | 503B 3.23B | Net Debt 2025 * | 512B 3.29B | EV / Sales 2025 * | 1.9 x |
P/E ratio 2024 |
173
x | P/E ratio 2025 * |
29.9
x | Employees | 14,484 |
Yield 2024 |
4.26% | Yield 2025 * |
5.05% | Free-Float | 98.83% |
Latest transcript on Astellas Pharma Inc.
1 day | -1.75% | ||
1 week | -2.65% | ||
Current month | -1.78% | ||
1 month | +1.47% | ||
3 months | -11.22% | ||
6 months | -16.48% | ||
Current year | -11.80% |
Managers | Title | Age | Since |
---|---|---|---|
Naoki Okamura
CEO | Chief Executive Officer | 61 | 86-03-31 |
Kitamura Atsushi
DFI | Director of Finance/CFO | 52 | Oct. 31 |
Kenji Yasukawa
CHM | Chairman | 63 | 86-03-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Kenji Yasukawa
CHM | Chairman | 63 | 86-03-31 |
Naoki Okamura
CEO | Chief Executive Officer | 61 | 86-03-31 |
Tatsuro Ishizuka
BRD | Director/Board Member | 68 | 19-05-31 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
11.47% | 19 M€ | +11.32% | ||
2.09% | 240 M€ | +17.87% | ||
2.01% | 60 M€ | +22.66% | ||
1.99% | 10 M€ | +16.22% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-05-17 | 1,487 | -1.75% | 8,169,500 |
24-05-16 | 1,514 | -0.75% | 4,790,700 |
24-05-15 | 1,525 | +0.26% | 4,901,000 |
24-05-14 | 1,521 | +0.70% | 6,123,400 |
24-05-13 | 1,510 | -1.11% | 4,597,000 |
Delayed Quote Japan Exchange, May 17, 2024 at 02:00 am EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-11.80% | 17.15B | |
+32.09% | 693B | |
+29.39% | 584B | |
-1.34% | 372B | |
+20.34% | 332B | |
+7.39% | 294B | |
+14.25% | 239B | |
-3.03% | 211B | |
+10.02% | 210B | |
+8.49% | 168B |
- Stock Market
- Equities
- 4503 Stock